DEFA14A: Novartis to Acquire Avidity, Spin Off Cardiology Unit

Novartis AG plans to acquire Avidity Biosciences, Inc., which will first spin off its early-stage precision cardiology programs into a new independent entity, Atrium Therapeutics, Inc.

Summary

• Novartis AG will acquire Avidity Biosciences, Inc. through a merger with its indirect wholly owned subsidiary, Ajax Acquisition Sub, Inc., as per an Agreement and Plan of Merger dated October 25, 2025.
• Prior to the merger, Avidity will undergo a pre-closing reorganization, spinning off its early-stage precision cardiology programs and certain collaboration agreements into Atrium Therapeutics, Inc. (formerly Bryce Therapeutics, Inc., name changed on December 8, 2025), referred to as SpinCo.
• Avidity will either distribute SpinCo shares to its stockholders on a pro rata basis (1 share of SpinCo Common Stock per 10 shares of Avidity common stock) or consummate a sale of SpinCo to a third party.
• Following the Spin-Off, Avidity will have no continuing ownership interest in SpinCo.
• The Spin-Off includes certain assets that trigger a right of first negotiation with an existing collaboration partner.
• Stephen Moran, previously lead of the Novartis Radioligand Therapy Platform, will be appointed Managing Director of Avidity Biosciences following the closing of the proposed transaction.

Sentiment

Score: 7

Explanation: The filing communicates a significant corporate transaction (acquisition and spin-off) with a generally positive and forward-looking tone regarding the integration and future prospects under Novartis. However, it is heavily qualified by extensive risk disclosures inherent in such complex transactions, preventing a higher score.

Positives

• The acquisition by Novartis provides Avidity's remaining assets with the substantial resources and backing of a major global pharmaceutical company, potentially accelerating development and market access.
• The spin-off of early-stage precision cardiology programs into Atrium Therapeutics, Inc. allows for focused development and potentially unlocks value for these specialized assets as an independent entity.
• Novartis has appointed an experienced leader, Stephen Moran, to guide Avidity post-acquisition, signaling a commitment to successful integration and continued innovation within the new structure.

Risks

• The timing of the satisfaction of customary closing conditions, including regulatory approvals and Avidity stockholder approval, may not be met on acceptable terms or at all.
• Risks and costs related to the implementation of the SpinCo separation, including the ability to complete the separation in the anticipated timeframe, or at all, and any changes to the configuration of the businesses included in the separation if implemented.
• The sale of certain SpinCo assets is subject to a third-party right of first negotiation.
• The risk that competing offers or acquisition proposals for Avidity will be made.
• Potential disruption from the transactions and their impact on Novartis and Avidity's businesses, including their relationships with employees, business partners, or governmental entities.
• The transactions may be more expensive to complete than anticipated.
• Stockholder litigation in connection with the transactions may result in significant costs of defense, indemnification, and liability.
• Diversion of management's attention from ongoing business operations and opportunities as a result of the transactions.
• Uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data.
• Regulatory actions or delays or government regulation generally.
• There is no guarantee that Avidity's investigational products will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time.
• There is no guarantee that Avidity's approach to the discovery and development of product candidates based on its AOC platform will produce any products of commercial value.
• There is no guarantee that the expected benefits or synergies from the transactions will be achieved in the expected timeframe, or at all.

Future Outlook

The proposed acquisition of Avidity by Novartis and the related spin-off of SpinCo are expected to proceed, subject to customary closing conditions, regulatory approvals, and Avidity stockholder approval. Novartis aims to preserve Avidity's unique aspects and leverage its AOC platform and pipeline. The future success of Avidity's investigational products and the achievement of expected benefits and synergies from the transactions are subject to various risks and uncertainties.

Management Comments

• "We remain committed to ensuring business continuity and maintaining Aviditys scientific excellence."
• "Ensuring the progress of your programs for the benefit of patients will continue to guide our strategic ambitions."
• "We deeply respect what you have built at Avidity—the AOC platform, your pipeline, and the culture that underpins it all."
• "Our goal is to build on and strengthen that foundation, with transparency and stability, as we go forward together through the transition and beyond."
• "Until closing, it is very important we remember that Avidity and Novartis remain separate and independent companies. There is no change to your current structure or reporting lines and your focus should remain fully on delivering your programs for patients."

Industry Context

This transaction reflects a broader trend in the pharmaceutical and biotechnology industry where larger established companies acquire innovative smaller firms to expand their pipeline and technology platforms. The spin-off of early-stage assets into a separate entity is also a common strategy to unlock value and allow for more focused development in specialized therapeutic areas like precision cardiology, while the acquiring company integrates the more mature or synergistic assets.

Management Changes

Legal Proceedings

• Risk of stockholder litigation in connection with the transactions, which may result in significant costs of defense, indemnification, and liability.

Stakeholder Impact

• Shareholders: Will receive either cash (from merger, implied) or SpinCo shares, and will need to vote on the transaction. Their interests in the transactions will be detailed in the definitive proxy statement.
• Employees: Avidity employees will transition to being part of Novartis, with assurances of business continuity and maintaining scientific excellence. A new Managing Director has been appointed.
• Business Partners: Relationships with business partners could be affected by the disruption from the transactions.
• Collaboration Partner: An existing collaboration partner has a right of first negotiation regarding certain SpinCo assets.

Next Steps

• Novartis, Avidity, and SpinCo intend to file relevant documents with the SEC, including a definitive proxy statement by Avidity.
• The definitive proxy statement and proxy card will be delivered to Avidity stockholders in advance of a special meeting relating to the transactions.
• Avidity stockholders will need to approve the proposed transactions.
• Stephen Moran will visit Avidity during the week of January 12, 2026, to meet employees and introduce himself.
• Stephen Moran will work closely with the Avidity leadership team post-deal close to preserve Avidity's unique aspects and position it within Novartis.

Key Dates

Keywords

Novartis, Avidity Biosciences, Merger, Acquisition, Spin-Off, Atrium Therapeutics, Biotechnology, Pharmaceuticals, Cardiology Programs, SEC Filing, Corporate Governance